share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K:外国发行人报告
SEC announcement ·  03/20 16:43
Moomoo AI 已提取核心信息
RedHill Biopharma Ltd. has announced the postponement of its Extraordinary General Meeting of Shareholders, which was originally scheduled for March 20, 2024. The adjournment was due to the absence of the required legal quorum. The meeting has been rescheduled to take place the following day, March 21, 2024, at 3:00 p.m. Israel time at the company's office in Tel Aviv. This information was disclosed in a Form 6-K filing with the United States Securities and Exchange Commission. The Form 6-K is also incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3.
RedHill Biopharma Ltd. has announced the postponement of its Extraordinary General Meeting of Shareholders, which was originally scheduled for March 20, 2024. The adjournment was due to the absence of the required legal quorum. The meeting has been rescheduled to take place the following day, March 21, 2024, at 3:00 p.m. Israel time at the company's office in Tel Aviv. This information was disclosed in a Form 6-K filing with the United States Securities and Exchange Commission. The Form 6-K is also incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3.
RedHill Biopharma Ltd.宣布推迟原定于2024年3月20日举行的特别股东大会。休会是由于缺乏所需的法定人数。会议已改期为第二天,即2024年3月21日以色列时间下午3点在该公司位于特拉维夫的办公室举行。该信息是在向美国证券交易委员会提交的6-K表格中披露的。6-K表格还以引用方式纳入公司在S-8表格和F-3表格上的各种注册声明中。
RedHill Biopharma Ltd.宣布推迟原定于2024年3月20日举行的特别股东大会。休会是由于缺乏所需的法定人数。会议已改期为第二天,即2024年3月21日以色列时间下午3点在该公司位于特拉维夫的办公室举行。该信息是在向美国证券交易委员会提交的6-K表格中披露的。6-K表格还以引用方式纳入公司在S-8表格和F-3表格上的各种注册声明中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息